Saltar al contenido principal
Elsevier

Coronaviruses and other Novel Antiviral Targets

  • 1 Edición, Volumen 57 - 17 de noviembre de 2021
  • Última edición
  • Editor: Katherine Seley-Radtke
  • Idioma: Inglés

Annual Reports in Medicinal Chemistry, Volume 57 in this long-running series, highlights new advances in the field with this new volume presenting interesting chapters on the Mecha… Leer más

Descripción

Annual Reports in Medicinal Chemistry, Volume 57 in this long-running series, highlights new advances in the field with this new volume presenting interesting chapters on the Mechanism of action of the broadly acting antiviral drug remdesivir, Improving properties of the nucleobase analogue T-706 as a potential anti-SARS-CoV-2 and anti-influenza compound, Antivirals for RNA virus infections Anno 2020-2021, Broad spectrum antiviral fleximer nucleosides, SARS-CoV-2 main protease inhibitors, The search for antivirals to treat alphavirus infections, Inhibitors of Ebola Virus targeting Innate immune evasion, Uracil derivatives as non-nucleoside inhibitors of viral infections, and more.

Puntos claves

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in the Annual Reports in Medicinal Chemistry
  • Updated release includes the latest information on the Coronaviruses and other novel antiviral targets

De interès para

Undergraduates, graduates, academics, and researchers in the field of medicinal chemistry

Índice

1. Improving properties of the nucleobase analogs T-705/T-1105 as potential antivirals

Chris Meier

2. Anno 2021: Which antivirals for the coming decade?

Piet Herdewijn and Eric De Clercq

3. Broad spectrum antiviral fleximer nucleosides

Katherine L. Seley-Radtke, Joy E. Thames and Charles D. Waters III

4. The search for antivirals to treat alphavirus infections

Andrea Brancale and Marcella Bassetto

5. Inhibitors of Ebola Virus targeting Innate immune evasion

Enzo Tramontano, Angela Corona and Anna Laura Paulis

6. Uracil derivatives as non-nucleoside inhibitors of viral infections

Anastasia Khandazhinskaya

Detalles del producto

  • Edición: 1
  • Última edición
  • Volumen: 57
  • Publicado: 17 de noviembre de 2021
  • Idioma: Inglés

Sobre el editor

KS

Katherine Seley-Radtke

Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as the Program Director for UMBC’s Chemistry-Biology Interface graduate training program funded by NIH since 2007. This program promotes hands on cross disciplinary research for almost 50 PhD students from four departments at UMBC and UMB. She is currently the Immediate Past President and Secretary-Elect for the International Society of Nucleosides, Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy, Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Afiliaciones y experiencia
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USA

Ver libro en ScienceDirect

Lee Coronaviruses and other Novel Antiviral Targets en ScienceDirect